Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

Loading... In May, Gossamer Bio and Italy-based Chiesi Farmaceutici S.p.A entered a global collaboration and license agreement to develop and commercialize seralutinib. The analyst adds that Gossamer has strategically positioned seralutinib to enter large, underserved markets such as Japan. "We see shares trading below cash as creating an attractive entry point at current levels." Gossamer Bio is focused on developing and commercializing seralutinib for pulmonary arterial hypertension. It stands out with it ...